Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies (Nasdaq: DBVT, Euronext: DBV) has filed an automatically effective shelf registration statement on Form S-3ASR with the SEC, including a base prospectus and a sales agreement prospectus supplement, to refresh its existing at-the-market offering program for up to $150 million of American Depositary Shares (ADSs).
The ATM program, conducted under a September 5, 2025 sales agreement with Citizens JMP Securities acting as sales agent, keeps total capacity at $150 million by carrying forward previously registered but unsold ADSs and adding newly registered capacity. Each ADS represents five ordinary shares, and issuances are subject to French regulatory limits, including a Prospective Regulation exemption for offerings to qualified investors representing less than 30% of securities already admitted over 12 months. DBV intends to use any net proceeds mainly for manufacturing expansion, BLA activities in ages 1–3 and 4–7, potential launch preparation of Viaskin Peanut in ages 4–7 if approved, product development, and general corporate purposes.
DBV Technologies (Nasdaq: DBVT) announced that it has filed its 2026 Half-Year Report for the semester ended June 30, 2026 with the French market authority, Autorité des Marchés Financiers (AMF). According to the company, the report is available in French on its website under Investors/Financial Information and on the AMF website.
DBV Technologies (Nasdaq: DBVT) reported second quarter and half-year 2026 results, highlighting continued regulatory progress for the VIASKIN® Peanut Patch in children aged 4–7 years. The company is engaged in detailed, ongoing interactions with the FDA and now anticipates submitting its BLA in the third quarter of 2026, with no additional data requested to date.
DBV closed enrollment in the COMFORT Toddlers safety study, initiated the THRIVE study in infants, and remains funded into the third quarter of 2027, supported by $174.9 million in cash and cash equivalents at June 30, 2026. For the first half of 2026, operating income was $1.6 million, operating expenses $100.1 million, and net loss $98.0 million, or $(0.23) per share, compared with a $(0.58) loss per share a year earlier. Net cash used in operating and investing activities rose to $102.6 million, reflecting increased clinical, manufacturing, and commercial readiness investments.
DBV Technologies (Nasdaq: DBVT) announced it will report its second quarter 2026 financial results and provide a business update on July 16, 2026. The company will host an investor conference call and live audio webcast at 5:00 p.m. ET to review these results.
DBV Technologies (Nasdaq:DBVT) released its half-year report on the liquidity contract with ODDO BHF for its shares.
As of June 30, 2026, the liquidity account held 146,321 shares and €396,088.22, after trading 2.7 million purchased and 2.6 million sold shares in H1 2026.
DBV Technologies (Nasdaq:DBVT) updated plans for its Biologics License Application (BLA) for the VIASKIN Peanut Patch in children aged 4–7 years. The company has held detailed, iterative discussions with the FDA, receiving feedback on organizing existing CMC and biostatistical data, with no additional data requested.
DBV now anticipates submitting the BLA in the third quarter of 2026 and will host an investor conference call and webcast on June 29 at 5:00 p.m. ET to discuss the update.
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharma company, announced its inclusion in the Euronext Tech Leaders index, effective June 22, 2026.
The index highlights high-growth European tech and adjacent-sector companies. DBV links this recognition to its progress advancing the VIASKIN Peanut Patch for children with peanut allergy.
DBV Technologies (Nasdaq: DBVT), a late-stage biopharmaceutical company, will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami, FL.
CEO Daniel Tassé will not attend the previously scheduled fireside chat due to travel disruption.
DBV Technologies (Nasdaq:DBVT) will present new data on its VIASKIN Peanut Patch at the EAACI Congress 2026. Phase 3 VITESSE subgroup results in children aged 4–7 with asthma, other food allergies or atopic dermatitis showed statistically significant efficacy vs placebo, with responder rates broadly around 47% vs 15%. DBV will also preview the Phase 2 THRIVE study design in approximately 250 infants aged 6–12 months, which will evaluate ad lib peanut consumption after three years of epicutaneous immunotherapy treatment.
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for June 9, 2026, at 9:20 AM ET in Miami, with a live webcast and 90-day replay on the company’s investor website.